A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
On October 22, 2026, The Citizen published “Breaking silence on men’s midlife hormonal changes,” a report from Dar es Salaam about testosterone and men’s sexual and emotional wellbeing. The report emphasized professional support for persistent changes rather than assuming that every concern is an unavoidable part of ageing.
Its central distinction matters: gradual testosterone decline is not a universal male equivalent of menopause. The clinicians quoted described different experiences between men. They also addressed the embarrassment that can surround changes in sexual function and the importance of discussing fertility before considering testosterone therapy.
The useful message is neither to dismiss a change nor to give it a hormonal explanation immediately. It is to make room for assessment and a more open conversation.
The report draws on commentary from physician Dr Julius Twoli and psychologist Cosmas Maduhu. Twoli discusses age-related testosterone change and medical assessment. Maduhu addresses the emotional and relationship context, including expectations about how men should respond to difficulties.
The article’s scope extends beyond sexual symptoms. It considers energy and sleep alongside mood and confidence. That breadth reflects the questions readers may bring to a consultation: whether several changes belong together and whether hormones might be involved.
Professional guidance provides a separate clinical foundation for interpreting the report. The European Association of Urology (EAU) guideline addresses male hypogonadism and its assessment. A September 2026 statement from the Endocrine Society addresses testosterone screening in men without symptoms. These sources concern clinical decisions rather than the personal experience of navigating midlife.
The Citizen distinguishes gradual testosterone decline from menopause. It describes menopause as the permanent end of menstruation after 12 consecutive months without a period. The account of testosterone change is different: there is no single transition that all men experience in the same way.
Quoting Twoli, the report describes an approximate 1% annual testosterone decline beginning around ages 30 to 40. It also emphasizes differences in timing and impact. Some men notice symptoms in their 40s and 50s. Others notice them after 60, while many remain healthy and active without significant symptoms.
That variation is central to the story. The report does not describe midlife as a deadline after which men should expect to lose sexual wellbeing.
The experiences discussed in The Citizen include:
The report also considers effects on confidence and relationships. Its advice is to seek professional support when changes persist rather than simply attributing them to age.
Keeping desire and physical response distinct provides useful language for that discussion. Describing the experience is a clearer starting point than choosing a diagnosis before an assessment.
Maduhu told The Citizen that expectations of strength and emotional resilience can make it harder for some men to acknowledge changes or seek help. His contribution places the subject within everyday relationships rather than treating it only as a laboratory question.
He emphasized communication and emotional support between partners. The report also relayed his advice to avoid unverified remedies. Together, these points support taking concerns seriously without turning uncertainty into pressure to find a product or an immediate hormonal explanation.
This update is a newspaper report based on expert commentary, not an experimental or observational study with a defined research population. It provides no research sample size or follow-up period from which to estimate symptom prevalence or compare outcomes.
The approximate annual decline is a general description rather than a personal forecast. The symptoms discussed also do not establish that low testosterone caused them. The account does not separate hormonal influences from other physical, psychological or relationship contributors in individual cases.
The lifestyle suggestions require similar care. The report mentions exercise and balanced eating alongside other general wellbeing measures. It does not provide trial data showing that those measures treat diagnosed testosterone deficiency.
The accompanying professional documents are clinical guidance and a screening statement. They should not be read as treatment results from the newspaper story. The strongest use of this evidence is to frame appropriate questions and explain assessment, not to predict an individual man’s hormone levels or treatment needs.
The EAU guideline describes male hypogonadism as a clinical syndrome involving symptoms, with or without signs, alongside biochemical evidence of testosterone deficiency. Put simply, the clinical picture and laboratory evidence belong together.
This supports the report’s call for assessment rather than self-diagnosis. Recognizing a change is a reason to ask a question. It is not the same as establishing its cause.
The EAU recommends morning, fasting total-testosterone measurement and repeating low results on at least two separate occasions before starting treatment. These are elements of clinical assessment rather than instructions to arrange tests independently. The practical point is that treatment decisions involve more than matching a symptom list to a single laboratory result.
No such conclusion follows from the report. In September 2026, the Endocrine Society stated that evidence was insufficient to support population-level testosterone screening for hypogonadism in asymptomatic men.
Evaluating persistent symptoms and screening people without symptoms are different questions. The news report concerns men who have noticed changes. The Society’s statement addresses testing across a population without symptoms. Keeping those purposes separate avoids turning awareness of testosterone into an expectation that every man needs a test.
This distinction also leaves room for qualified clinicians to assess concerns without suggesting that midlife itself is an illness.
The fertility caution in The Citizen aligns with the EAU guideline. Testosterone supplied as medication can suppress pituitary hormone signals involved in sperm production and maturation.
The EAU states that testosterone therapy is contraindicated for men with hypogonadism who are seeking fertility treatment. This is an important distinction between treating testosterone deficiency and supporting fertility. They should not be assumed to be the same goal.
For men who may want children, fertility intentions therefore belong in the conversation before treatment is considered. The report’s call for medical supervision is particularly relevant here. A discussion focused only on desire or energy could leave an important personal priority unspoken.
For someone experiencing persistent changes, the report supports professional assessment rather than resignation or self-diagnosis. That does not mean every variation is a medical problem. It means that an age label need not settle an unanswered question.
A useful conversation begins with the experience itself. Reduced interest is a different description from difficulty maintaining an erection. A change in sleep or mood also deserves its own words rather than automatically becoming part of a testosterone story.
Sexential’s guide to putting sexual-health concerns into words offers related educational context. The purpose is to help make a concern understandable, not to arrive with a predetermined diagnosis or request for treatment.
The communication advice reported by The Citizen supports a non-judgmental discussion of changes in intimacy and confidence. A conversation might begin with what feels different rather than a theory about why it is happening.
That leaves space for a person to describe concern or uncertainty without having to defend their strength or sexual identity. Partner support can accompany professional input. It does not need to supply a medical explanation.
Recognizing individual patterns of midlife change also keeps the discussion from becoming a comparison with someone else’s experience. The report’s emphasis is on variation rather than a shared timetable.
The report mentions exercise and a balanced diet alongside healthy weight, sleep and limiting alcohol. These belong in a general wellbeing conversation. Its more immediate message for persistent concerns is to seek appropriate medical or psychological support and avoid unverified remedies.
The overall shift is from naming a supposed midlife condition to describing a real experience clearly. Hormones may be part of the assessment, while confidence and relationships remain part of the conversation.
Today, put your main question about a persistent change into words for a conversation with a qualified clinician.
Sorting out whether a persistent midlife change needs medical discussion is where Sexential’s educational role begins. When hormonal explanations compete with physical concerns or emotional and relationship questions, its mature educational coverage helps readers understand the overlapping factors and prepare clearer questions without assigning a diagnosis or selecting treatment.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
A midlife health guide includes low desire in a broader health conversation. Read the clinical context, evidence limits and practical meaning.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
